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Objectives This study sought to assess the safety and effectiveness of a novel cryoballoon ablation technology designed to
achieve single-delivery pulmonary vein (PV) isolation.
Background Standard radiofrequency ablation is effective in eliminating atrial fibrillation (AF) but requires multiple lesion
delivery at the risk of significant complications.
Methods Patients with documented symptomatic paroxysmal AF and previously failed therapy with 1 membrane active
antiarrhythmic drug underwent 2:1 randomization to either cryoballoon ablation (n  163) or drug therapy (n  82).
A 90-day blanking period allowed for optimization of antiarrhythmic drug therapy and reablation if necessary.
Effectiveness of the cryoablation procedure versus drug therapy was determined at 12 months.
Results Patients had highly symptomatic AF (78% paroxysmal, 22% early persistent) and experienced failure of at least one
antiarrhythmic drug. Cryoablation produced acute isolation of three or more PVs in 98.2% and all four PVs in 97.6%
of patients. PVs isolation was achieved with the balloon catheter alone in 83%. At 12 months, treatment success was
69.9% (114 of 163) of cryoblation patients compared with 7.3% of antiarrhythmic drug patients (absolute difference,
62.6% [p  0.001]). Sixty-five (79%) drug-treated patients crossed over to cryoablation during 12 months of study
follow-up due to recurrent, symptomatic AF, constituting drug treatment failure. There were 7 of the resulting 228
cryoablated patients (3.1%) with a 75% reduction in PV area during 12 months of follow-up. Twenty-nine of 259
procedures (11.2%) were associated with phrenic nerve palsy as determined by radiographic screening; 25 of these
had resolved by 12 months. Cryoablation patients had significantly improved symptoms at 12 months.
Conclusions The STOP AF trial demonstrated that cryoballoon ablation is a safe and effective alternative to antiarrhythmic medica-
tion for the treatment of patients with symptomatic paroxysmal AF, for whom at least one antiarrhythmic drug has
failed, with risks within accepted standards for ablation therapy. (A Clinical Study of the Arctic Front Cryoablation Bal-
loon for the Treatment of Paroxysmal Atrial Fibrillation [Stop AF]; NCT00523978) (J Am Coll Cardiol 2013;61:
1713–23) © 2013 by the American College of Cardiology Foundation
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The STOP AF Pivotal Trial April 23, 2013:1713–23Pulmonary vein (PV) isolation is
an effective treatment for patients
with symptomatic paroxysmal
atrial fibrillation (PAF) (1–2).
Recent clinical trials have dem-
onstrated that ablation success
rates at 12 months are generally
in the 60% to 75% range (3–6).
Nevertheless, the radiofrequency
(RF) ablation used in these trials
requires tedious point-to-point
delivery of multiple applications
to isolate PVs (1,3–7) and is
associated with complications
such as PV stenosis and atrial-
esophageal fistula (8).
See page 1724
Cryoablation balloon therapy
has been developed and tested
as an alternative, single-delivery
approach to isolation of PVs (9).
Acceptable success rates with low
adverse event rates have been re-
ported in large European observa-
tional studies (10–14). Neverthe-
less, the safety and effectiveness of
cryoballoon ablation have not been
tested in large randomized clinical
trials. The STOP AF trial was
undertaken to test the hypothesis
that cryoballoon ablation would
produce a significantly greater treat-
ment success than antiarrhythmic
drug therapy in achieving freedom
from AF with an acceptable safety
profile.
Methods
The STOP AF trial was a pro-
spective, multicenter, random-
ized, controlled study designed
to compare outcomes of cryoab-
lation and antiarrhythmic drug
therapies in patients with PAF
and was designed in confor-
mance with U.S. Food and Drug
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Acronyms
AF  atrial fibrillation
AHA/ACC  American Heart
Association/American
College of Cardiology
A-V  atrio-venous
CAD  coronary artery
disease
CHADS2  congestive
heart failure, hypertension,
age, diabetes and stroke
scale
CHF  congestive heart
failure
CPE  cryoablation
procedure event
CT  computed
tomography
ECG  electrocardiogram
FDA  Food and Drug
Administration
ICE  intracardiac
ultrasound
INR  international
normalization ratio
LA  left atrium
LC  left common
LI  left inferior
LS  left superior
MAFE  major atrial
fibrillation event
MI  myocardial infarction
MR  magnetic resonance
PAF  paroxysmal atrial
fibrillation
PV  pulmonary vein
RF  radiofrequency
RI  right inferior
RM  right middle
RS  right superior
SF-36  Short Form-36
TIA  transient ischemic
attack
TTM  trans-telephonic
monitoring
UCB  upper confidence
boundcompensation) and a board member for Pfizer, Biosense Webster, CardioInsight
Scientific, and Sequel (no personal compensation); a compensated consultant withAdministration (FDA) guidance documents. The study
design (Fig. 1) was approved by the institutional review
board at each center and the Office of Device Evaluation,
FDA. Patients with more than 2 episodes of PAF in the 2
months prior to randomization, for whom at least one
membrane-active drug had failed, were eligible for enroll-
ment. Patients were excluded for a left atrium (LA) 5.0
cm, a left ventricular ejection fraction 40%, New York
Heart Association functional class III or IV congestive heart
failure (CHF), coronary artery disease warranting interven-
tion, stroke or transient ischemic attack (TIA) within 6
months, previous LA ablation or surgery for AF, a pros-
thetic heart valve, amiodarone therapy in the preceding 3
months, more than 2 cardioversions within 2 years, or an
implantable rhythm device. After providing written in-
formed consent, patients were randomized 2:1 to receive
cryoablation or antiarrhythmic drug therapy with flecainide,
propafenone, or sotalol.
Cryoablation therapy. The goal of cryoablation was elec-
trical PV isolation of the four major PVs (left inferior [LI],
left superior [LS], right inferior [RI], right superior [RS]) as
confirmed by entrance and/or exit block. Combined com-
mon left PVs were likewise ablated to achieve similar
blockage within the constituent PVs. Transseptal catheter-
ization was performed under fluoroscopic or intracardiac
echocardiography (ICE) guidance using a standard trans-
septal sheath, which was increased to a 15-F (Medtronic,
Inc., Minneapolis, Minnesota) FlexCath steerable sheath.
Thereafter, a 23- or 28-mm (Medtronic, Inc.) Arctic Front
cryoablation balloon catheter was advanced over a guidewire
to the orifice of the PV. Balloon selection was based on the
PV size as established by preprocedure computed tomogra-
phy (CT) or ICE. Cryoablation was performed in 240-s
deliveries, with assessment of entrance and/or exit blockage
by using pacing and a circular mapping catheter after a
30-min waiting period. Additional focal cryoablation deliv-
eries were made at investigator discretion, using an 8-mm
tipped cryoablation catheter (Freezor MAX cryoablation
catheter; Medtronic) if isolation was not achieved by one or
more cryoballoon ablations or if required for the ablation of
focal triggers. Cavotricuspid isthmus ablation using this
catheter was undertaken in patients with prior clinical or
inducible cavotricuspid isthmus-dependent atrial flutter,
with bidirectional block required. At the completion of the
procedure, pacing was used to demonstrate entrance and,
where assessable, exit block; isoproterenol use was optional,
and adenosine was not used to confirm the block.
Ablation was undertaken with the patient receiving hep-
arin, with an activated clotting time 300 s. Sedation
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and Third Rock Ventures; and receives honoraria for lectures from Med-IQ and holds
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April 23, 2013:1713–23 The STOP AF Pivotal Trialand/or anesthesia and reversal of anticoagulation were
performed according to the site’s standard practices. Prior to
discharge, cryoablation patients underwent repeated inspira-
tory and expiratory chest radiographic examinations to
screen for phrenic nerve palsy. Anticoagulation with warfa-
rin to a target international normalization ratio (INR) of 2.0
to 3.0 was required for the first 3 months after ablation.
Subsequently, warfarin was discontinued at the investiga-
tor’s discretion, as guided by published clinical guidelines
(15). During the 90-day blanking period, patients could
be empirically treated with an FDA-allowed antiarrhyth-
mic study drug (flecainide, propafenone, or sotalol), after
which the drug was discontinued. One repeat cryoabla-
tion procedure was permitted during this blanking pe-
riod, with the recommendation that all repeated ablations
use the same cryoablation method. Nevertheless, the final
decision about the mode of reablation was left to the
investigator. Use of RF energy for reablation was taken as
a treatment failure.
Drug therapy. Patients randomized to receive drug therapy
received flecainide, propafenone, or sotalol, if they had not
previously experienced failure with these drugs. Drug dos-
ages were optimized within approved labeling according to
the 2006 AHA/ACC guidelines for treatment of AF (15).
If necessary, a change to one of the other three drugs was
allowed. Once the patient was stabilized, the drug therapy
was maintained throughout the study. AF drugs such as
dofetilide and amiodarone were precluded by the FDA, as
they had not previously received approval for treatment of
PAF. Patients were allowed to cross over to cryoablation
treatment only after meeting protocol-defined effectiveness
failure endpoints. AF documentation during the blanking
period was required prior to crossing over to an alternate
Figure 1 Design of the STOP AF Cryoballoon Ablation Study
See Methods for details.treatment strategy.Follow-up. All patients, including those drug patients who
crossed over to ablation, were followed for 12 months after
their therapy initiation date. Each patient underwent re-
peated assessments at 1, 3, 6, 9, and 12 months. Occur-
rences of AF during the blanking period were not counted
against the primary objective, nor considered to be chronic
treatment failures. Personal trans-telephonic monitoring
(TTM) systems were provided for weekly scheduled trans-
missions and recordings at the occurrence of arrhythmia
symptoms. Twenty-four-hour Holter monitoring was re-
quired at 6 and 12 months. Repeated CT or magnetic
resonance (MR) imaging studies of PV anatomy were
conducted at baseline, 6, and 12 months and read, as were
electrocardiography (ECG) strips, by independent ECG
and imaging core laboratories. All clinical adverse events
and trial endpoints were reviewed and adjudicated by an
independent clinical events committee. Screening for Na-
tional Institutes of Health Stroke Score was performed at
each visit; with potential strokes/TIAs reviewed by the
study neurologist. Compliance was high for follow-up visits
(95%), weekly TTMs (90%) and Holters (90%),
postprocedural chest radiography (95%), and CT/MRI
studies (95%).
Endpoints. The primary effectiveness endpoint for the trial
was freedom from chronic treatment failure, as defined by
the absence of: 1) any detectable AF after the blanking
period; 2) use of a nonstudy, antiarrhythmic drug; or 3) any
nonprotocol intervention for AF (i.e., RF ablation). Free-
dom from AF after ablation while being treated with a
previously ineffective antiarrhythmic drug at the same or a
lower dose was considered a treatment success if patients
remained in sinus rhythm.
Two inferential coprimary safety endpoints were evalu-
ated for study success: 1) the proportion of intent-to-treat-
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related event (CPE); and 2) an intent-to-treat comparison
of the freedom from major AF events (MAFE) between
groups over 12 months of follow-up. CPEs were defined as
device- and procedure-related serious adverse events in the
following categories: access site complications, cardiac dam-
age (including myocardial infarction [MI]), embolic com-
plications (including stroke), arrhythmias, persistent
phrenic nerve palsy, PV stenosis, and death. MAFEs were
defined as nonprocedure-related serious adverse events in-
cluding: cardiovascular death, hospitalization for AF recur-
rence or ablation, atypical atrial flutter ablation, systemic
embolization, CHF, nonstroke hemorrhagic events, MI,
stroke, or antiarrhythmic drug initiation, adjustment or
complications requiring hospitalization. In addition, the
overall safety profile of the cryoablation procedure was
reported as event rates for all ablated patients (“on treat-
ment”) including those crossing over from drug therapy.
Statistical analysis. The results of continuous variables are
iven as mean  SD. Comparisons were made using paired
or Kruskal-Wallis testing as appropriate for the distribu-
ion of values. Categorical variables were compared using
xact binomial or chi-square analyses. Long-term outcomes
ere expressed using Kaplan-Meier statistics, with the
ignificance of differences in values indicated by log-rank
esting. Differences between groups were also established
sing proportional hazards models. The primary effective-
ess endpoint (proportion of patients with treatment success
t 12 months) was assessed using a 2-sided Fisher’s exact
est of binomial proportions. The proportion of cryoablation
atients with freedom from cryoablation procedure events
as compared to a fixed proportion of 14.8%, using an exact
-sided binomial test, and the proportion of patients with
AFEs in the cryoablation group was compared with those
n the drug-treated group, using a noninferiority margin of
0%. A p value of 0.05 was viewed as significant.
esults
atient characteristics. A total of 245 patients were ran-
omized and enrolled over 21 months; 163 patients were
ssigned to cryoablation and 82 to antiarrhythmic drugs.
hirty-one cryoablation patients underwent a repeat cryo-
blation during the blanking period. Sixty-five drug-treated
atients crossed over to cryoablation after recurrent AF, and
drug-treated patients were lost to follow-up.
General patient characteristics were similar in both treat-
ent arms (Table 1). Randomized patients were highly
ymptomatic with 23.2 and 21.2 self-reported AF episodes
nd 14.4 and 11.1 episodes of rapid heartbeat in the ablated
nd drug arms, respectively, in the 2 months prior to
nrollment. Prior cardioversion and a history of atrial flutter
n the ablated and drug arms were similar. The median
umber for whom antiarrhythmic drugs failed prior to
nrollment was 1.3 in the cryoballoon-treated arm and 1.4
n those receiving antiarrhythmic drug therapy (p  NS).hese patients were also at low risk of stroke as judged by
ongestive heart failure (C), hypertension (H), age 75 or older
A), diabetes (D), and previous stroke (S2) (CHADS2) score of
0.6 to 0.7 (Table 1), without differences between groups.
Effectiveness outcome: acute cryoablation success. In the
163 intent-to-treat patients randomized to ablation, 655
PVs were cryoablated at the initial procedure. In 160
(98.2%) patients, 3 or more PVs were isolated as manifested
by entrance and/or exit the block. All 4 major PVs were
isolated in 97.6% of patients, as were 21 of 21 left common
(LC) PVs and 10 of 13 right middle (RM) PVs. In 83% of
patients, cryoballoon intervention alone was sufficient for
PV-isolating ablative therapy, with a total of 12.5  0.31
applications required for all PVs. The average cryoballoon
application time was 214.4 1.5 s/application. Cryoballoon
temperature averaged 51.0°C  0.4°C.
Twenty-seven patients required additional catheter-based
focal cryoablation in one or more PVs and at non-PV sites
in 8 (4.9%) patients; the need for focal cryoablation was not
significantly associated with the use of a particular size
cryoballoon. A 23-mm balloon was used in 61.4% of the
veins, while a 28-mm balloon was applied in 58.5%. Both
23- and 28-mm balloons were used in 20.8% of PVs. In the
19 PVs where isolation could not be achieved by cryoballoon
ablation alone, an average of 2.2 cryoablations were at-
tempted, including in one LC, 3 RMs, 4 LI (mean diameter
12.3 mm), 5 LS (mean diameter 14.4 mm), 3 RI (mean
diameter 16.4 mm), and 3 RS (mean diameter 21.5 mm)
PVs. Twelve of the nonisolated PVs were initially treated
with a 23-mm cryoballoon and seven with a 28-mm
cryoballoon. In each case where the PV could not be
isolated, the cryoballoon used was at least 2 mm larger than
the diameter of the PV.
The mean procedure duration including all repeat PV
assessment was 371 min, fluoroscopy exposure averaged 63
min, and total cryoablation time averaged 66 min. Over the
course of the trial, the percentage of patients undergoing
ablation with a 28-mm balloon remained consistent. The
cavotricuspid isthmus was cryoablated in 66 (40.5%) pa-
tients, with bi-directional block achieved in 64 (97.0%).
Long-term success: cryoablation group by intention to
treat. After 12 months of follow-up, freedom from chronic
treatment failure was seen in 114 of 163 (69.9%)
cryoballoon-ablated patients (Fig. 2). This included 13
(8.0%) patients for whom previous drug treatment was
ineffective at the same or received a lower dose after the
blanking period. Four patients were receiving flecainide, 200
mg daily, 4 were receiving propafenone, 450 to 675 mg
daily, and 5 patients were receiving sotalol, 30 to 240 mg
daily. The single procedure success rate was 57.7%, includ-
ing the 13 patients (8%) receiving previously ineffective
drugs as permitted by the protocol (9), in whom ultimate
success was seen in 69.9%, including the 31 patients (19%)
who underwent repeated cryoablation during the blanking
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April 23, 2013:1713–23 The STOP AF Pivotal Trialperiod. Only 6 (7.3%) patients randomized to the antiar-
rhythmic drug treatment arm remained free from chronic
treatment failure. The difference between ablation- and
drug-treated patients was highly significant (p  0.001)
Fig. 3A).
Of 163 patients, 121 (74.2%) received either flecainide,
ropafenone, or sotalol immediately after cryoablation, but
hese drugs were discontinued by the end of the blanking
eriod, as stipulated by the protocol. At the end of 12
onths, only 26% of ablation patients were taking antiar-
hythmic drugs; 95% of patients were treated with warfarin
pon enrollment, with only 24% of patients continuing this
edication at 12 months of follow-up. The CHADS2 score
was not different between those who stopped and those who
remained taking warfarin.
Symptomatic AF occurrence fell from 100% at baseline to
19.0% at 12 months. Arrhythmia-related symptoms were
Baseline CharacteristicsTable 1 Baseline Characteristics
Baseline and/or Demographics
Drug
(n  82)
Age (yrs) 56 9
Male (%) 78 (64/82)
Hypertension 45.1 (37/82)
Diabetes 8.5 (7/82)
CAD 9.8 (8/82)
Left atrial AP diameter (mm) 41 6
LV ejection fraction (%) 61 6
NYHA
None/I 93.9 (77/82)
Class II 6.1 (5/82)
AF episodes 21 32
Previous cardioversion 20.7 (17/82)
History of atrial flutter 43.9 (36/82)
CHADS2 0.6 0.7
Overall SF-36 70 15
Number of prior drugs failed
0 0.0 (0/82)
1 72.0 (59/82)
2 28.0 (23/82)
3 0.0 (0/82)
Failure more than 1 AF drug 28.0 (23/82)
Efficacy failed AF drugs
Flecainide 35.4 (29/82)
Propafenone 43.9 (36/82)
Sotalol 30.5 (25/82)
Baseline medication class
ACE-I 11.0 (9/82)
ARB 14.6 (12/82)
Beta-blocker 48.8 (40/82)
Calcium channel blocker 35.4 (29/82)
Cardiac glycoside/rate control 14.6 (12/82)
Cholesterol lowering 42.7 (35/82)
Diuretic 9.8 (8/82)
Values are mean  SD or % (n/N).
ACE-I  angiotensin-converting enzyme inhibitor; AFD  AF Drug
congestive heart failure, hypertension, age 75 or older, diabetes, anddramatically reduced in ablation patients by 12 months offollow-up: AF symptoms (100% to 20%), dizziness (48% to
9%), palpitations (86% to 25%), and fatigue (76% to 13%).
This symptomatic improvement was confirmed by improved
SF-36 quality of life subscores (16).
Drug treatment control group by intention to treat. Drug-
treated patients were tried on one or more drug therapies
during the blanking period, using flecainide (65%),
propafenone (57%), and/or sotalol (44%). Over the course
of the study, 65 of the 82 drug-treated patients (79%)
crossed over to ablative intervention. Eight (10%) highly
symptomatic drug-treated patients crossed over within the
blanking period. Seventeen patients crossed over at between
3 and 6 months of follow-up, and 40 additional patients
crossed over after the 6-month follow-up visit. All drug-
treated patients who crossed over during follow-up experi-
enced confirmed AF drug treatment failure requiring abla-
tive intervention. The median time to cross over was 186
Cryoablation
(n  163)
All
(n  245) p Value
57 9 57 9 0.80
76.7 (125/163) 77.1 (189/245) 0.87
41.1 (67/163) 42.4 (104/245) 0.59
6.7 (11/163) 7.3 (18/245) 0.61
8.0 (13/163) 8.6 (21/245) 0.64
40 5 41 5 0.35
60 6 60 6 0.41
93.3 (152/163) 93.5 (229/245) 1.00
6.7 (11/163) 6.5 (16/245)
24 42 23 39 0.54
22.7 (37/163) 22.0 (54/245) 0.87
46.0 (75/163) 45.3 (111/245) 0.79
0.6 0.7 0.6 0.7 0.92
71 18 71 17 0.87
0.76
0.6 (1/163) 0.4 (1/245)
69.9 (114/163) 70.6 (173/245)
28.2 (46/163) 28.2 (69/245)
1.2 (2/163) 0.8 (2/245)
29.4 (48/163) 29.0 (71/245) 0.88
36.8 (60/163) 36.3 (89/245) 0.89
49.1 (80/163) 47.3 (116/245) 0.50
28.8 (47/163) 29.4 (72/245) 0.88
15.3 (25/163) 13.9 (34/245) 0.35
10.4 (17/163) 11.8 (29/245) 0.34
41.1 (67/163) 43.7 (107/245) 0.25
27.6 (45/163) 30.2 (74/245) 0.21
8.0 (13/163) 10.2 (25/245) 0.10
34.4 (56/163) 37.1 (91/245) 0.20
16.0 (26/163) 13.9 (34/245) 0.19
anterior-posterior; ARB  angiotensin receptor blocker; CHADS2 
s stroke; LV  left ventricular; NYHA  New York Heart Association.(range 29 to 364) days. Only 6 (7.3%) patients randomized
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The STOP AF Pivotal Trial April 23, 2013:1713–23to the antiarrhythmic drug treatment arm remained free
from chronic treatment failure.
Long-term outcomes: On-treatment analysis. Including
the original randomized group of 163 patients and the 65
crossover patients for whom early drug treatment failed,
228 patients underwent cryoballoon ablation, providing a
more complete “on-treatment” analysis. The drug-
treated, cross-over patients were then followed for an
additional 12 months following cryoablation. A post-hoc
analysis of freedom from AF beginning 90 days after
cryoablation allowed comparison of the intent-to-treat
ablation patients with the cryoablated drug patients as
seen in Figure 3B.
Crossover drug-treated patients (n  65) had an esti-
mated rate standard error of the mean (SEM) of freedom
from any postblanking AF following cryoablation of 61.6 
7.3%. Intent-to-treat ablation patients (n  163) had an
stimated rate of freedom from any postblanking AF
ollowing first cryoablation of 63.7  4.1%. This difference
as not significant (p  0.9107, log-rank test).
afety outcomes: safety endpoints by intention to treat.
oth prespecified primary safety endpoints were met.
erious CPE occurred in 5 (3.1%) patients undergoing
ryoablation, with an upper confidence bound (UCB) of
.3%, which was well below the pre-specified UCB of
4.8% (p  0.001). One patient with pre-existing coro-
ary artery disease (CAD) and coronary artery bypass
raft sustained a periprocedural non–Q-wave MI, which
as attributed to anesthesia-induced hypotension; 1 pa-
ient developed tamponade; 2 patients developed symp-
Figure 2 Numerical Outcomes of AF Treatment
in the STOP AF Trial
Note patient withdrawals and screening failures. LTFU  lost to follow-up;
WD  withdrawals.omatic PV stenosis where intervention was recom- dended; and 1 patient had atrial flutter requiring
rolonged hospitalization.
MAFEs were seen in 5 (3.1%, UCB 7.0%) cryoablation
atients and 7 (8.5%, UCB 16.8%) drug-treated patients
noninferiority, p  0.001). Five cryoablation patients
xperienced MAFEs: 1 (0.6%) patient sustained an unre-
ated fatal MI at 10 months; 1 patient had Wegener’s-
elated hemoptysis, AF recurrence and hospitalization for
ntiarrhythmic drug adjustment; 1 patient had a subarach-
oid hemorrhage; 1 patient had intestinal bleeding accom-
anying an elevated INR; and 1 patient was hospitalized
ith AF-related CHF. There were 7 drug-treated patients
ho experienced 12 MAFEs, including hospitalizations for
F recurrence or ablation (5 of 82, 6.1%), antiarrhythmic
herapy adjustment (4 of 82, 4.9%), or treatment for atrial
utter (1 of 82, 1.2%). Two (2.4%) drug-treated patients
ad gastrointestinal or subdural bleeding complications.
The combined rate of cryoablation procedure events
nd MAFEs in the ablation arm was lower than the
AFE rate in drug-treated patients: 6.1 versus 8.5%,
espectively (p 0.001) (Fig. 4). The overall serious adverse
vent rates over 12 months were not different in the two
reatment arms: 12.3% in cryoablation and 14.6% in drug-
reated patients (p  0.688).
V stenosis. PV stenosis, defined as a reduction of
75% in cross-sectional area (approximately a 50%
eduction in diameter), occurred in 5 of 163 (3.1%)
ryoablated patients in the original randomized treatment
rm. In subsequent on-treatment analysis including the
5 patients who crossed over from drug to ablation
reatment, 7 (3.1%) of the 228 cryoablated patients (10
Vs) developed stenosis. Stenotic veins included 5
IPVs, 4 LSPVs, and 1 RIPV. A 23-mm cryoballoon
lone was used exclusively in 4 PVs, and both 23- and
8-mm cryoballoons were used in 6 PVs. PV stenosis
ccurred in 2.1% (4 of 186) of patients with only a single
ryoablation procedure and in 6.5% (2 of 31) of patients
ith 2 cryoablation procedures; 1 additional patient had
V stenosis after 2 procedures: the first with cryoablation
nd the second with RF ablation. Five patients were
symptomatic throughout follow-up, and 2 patients de-
eloped increasing dyspnea, which resolved in 1 patient
fter PV stenting. A second patient, refused intervention
nd was asymptomatic at 12 months of follow-up.
hrenic nerve paralysis. Phrenic nerve paralysis was as-
essed by inspiration/expiration chest radiography after 259
ryoablation procedures in 228 patients. Paralysis was doc-
mented after 29 of 259 (11.2%) procedures. Slightly more
han half the affected patients were asymptomatic; 1
ubject had paralysis following both the initial and repeat
ryoablations. Of the 28 patients with phrenic nerve
njury, 25 showed complete radiographic resolution over
mean 144  27 days. Four patients had persistent
adiographic abnormalities at 12 months of follow-up, 1
f whom had ongoing symptoms of mild cough and
yspnea. Of the 29 procedures resulting in phrenic nerve
1719JACC Vol. 61, No. 16, 2013 Packer et al.
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in 17 cases, a 28-mm balloon in 9 cases, with both sizes
in 2 cases, and with only the Freezor MAX catheter in
one reablation case.
Stroke occurrence/neurologic events. Stroke occurred in
5 of 228 (2.2%) randomized and crossover cryoablated
patients. One procedure-related stroke occurred on the day
of intervention in a patient crossing over from drug to
cryoablation therapy, which was the only procedure- related
stroke event (0.4%, 1 of 228). An additional 4 patients
sustained nonprocedure-related cerebral vascular events over
follow-up. In 1 postablation patient, a small hemorrhagic
stroke occurred on day 183 of follow-up, 5 days after RF
ablation for atrial flutter. A second patient demonstrated a
lacunar infarct of indeterminate age on CT examination on
Figure 3 Procedural Success Given as Freedom From CTF as a
(A) Intention-to-treat primary effectiveness endpoint for freedom from chronic treat
drugs. (B) Freedom from any AF between the on-treatment cryoablation and drug-tday 51. An additional patient had transient bilateral visualdisturbance, occurring one month after cryoablation, with
no abnormalities by CT scan. Subarachnoid hemorrhage
occurred on day 260 in an additional patient on aspirin.
Symptom severity was mild in 3 and severe in 2 at the onset
of the event. All patients recovered without residual neuro-
logical deficits.
Four additional patients sustained apparent TIAs. One
occurred 3 days after ablation. Dizziness occurred in a
second patient on the day of ablation, with full resolution
of symptoms within several minutes. Transient left lower
arm and hand numbness was noted in a fourth patient 19
days after ablation. Temporary amaurosis fugax was
experienced 9 days after ablation in a crossover patient.
Other adverse events. No patient developed an atrial-
esophageal fistula. Myocardial perforation and vascular in-
tion of Time
failure (CTF) between patients treated with cryoablation and those treated with
patients. KM  Kaplan-Meier estimates; OR  odds ratio.Func
ment
reatedjury were uncommon. A femoral arteriovenous fistula oc-
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aneurysms. Postprocedure cough developed following 44 of
259 (17%) procedures, which resolved completely in 91% of
patients by the end of the study. The median time to
recovery in 33 patients was 39 (range 0 to 272) days.
Pericardial chest pain following ablation was uncommon.
Serious adverse events occurred in 34 of 228 (14.9%)
cryoablated patients: 11 (4.8%) patients had one or more
serious adverse events that were either device- or procedure-
related. The safety outcomes of all 228 patients treated with
cryoballoon ablation are provided in Table 2.
Figure 4 Cryoablation Procedural Events in Patients Undergoin
Pre-specified upper confidence event rate provided for on-treatment analysis (dash
Summary of Adverse Events On-Treatment AnalyTable 2 Summary of Adverse Events On-Tre
Type of Adverse Event
Drug Treatment
(N  82)
No. of Events %
Stroke 0 0.
TIA 0 0.
Tamponade 0 0.
Myocardial infarction 0 0.
Hemorrhage requiring transfusion 1 1.
New atrial flutter 12 14.
Atrial esophageal fistula 0 0.
Death 0 0.
New or worsened arteriovenous
fistula
0 0.
Pseudoaneurysm 0 0.
Phrenic nerve palsy 0 0.
Persistent phrenic nerve palsy 0 0.
PV stenosis 0 0.PV  pulmonary vein; TIA  transient ischemic attack.Discussion
Chief findings. The Arctic Front STOP AF trial demon-
strates a persistent benefit of cryoballoon-based ablation for
PAF, with an effectiveness rate that was significantly greater
than that seen with antiarrhythmic drug therapy over 12
months of follow-up in highly symptomatic patients with
AF, failing treatment with at least one antiarrhythmic drug.
This study also demonstrates a low serious adverse event rate,
although minor adverse events did occur. Nevertheless, PV
stenosis, phrenic nerve injury, and stroke remain potential
complications, as detected by complete screening in this trial.
ation
). MAFE  major AF events.
nt Analysis
Cryoablation
(N  163)
All Cryoballoon-
Treated
(N  228)
o. of Cryoablation Events % All Events %
4 2.5 5 2.2
3 1.8 4 1.8
1 0.6 2 0.9
2 1.2 2 0.9
3 1.8 3 1.3
6 3.7 8 3.5
0 0.0 0 0.0
1 0.6 1 0.4
2 1.2 2 0.9
1 1.6 2 0.9
22 13.5 28 12.3
4 2.5 4 1.8
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cess rate was higher than that predicted by a recent
meta-analyses of randomized and observational studies (17)
of standard RF ablation, suggesting the potential for sim-
plification of the ablation process by eliminating the need
for point-to-point manipulation of the catheter. Overall
outcome is similar to that suggested by a recent meta-
analysis of cryoballoon studies (14), as accomplished with
acceptably low redo rates. Randomized cryoablation versus
RF ablation studies will be required to more directly
establish the comparative impact of energy type, investigator
experience, underlying disease, AF type, and the compara-
tive requirement of additional LA or RA lesions beyond PV
isolation alone (18–20).
Procedure and cryoablation delivery times were longer
than seen in some prior studies of RF or cryoablation
(7,10–13), but are similar to the average times seen in
earlier, observational, cryoablation studies (14). This reflects
the inclusion of all patients from the beginning of an
individual operator’s experience with cryoballoon technol-
ogy. Protocol-mandated study components, particularly the
30-min assessment period at the end of the ablation, also
contributed to lengthy procedure times. With incremental
experience, the procedure and cryoablation delivery times
decreased, and single procedure success rates increased,
reflecting an expected learning curve.
The efficacy of cryoablation was also demonstrated by the
ability to discontinue antiarrhythmic drug and warfarin
therapy in three quarters of these patients over follow-up.
Nevertheless, these data from low-risk patients do not
necessarily apply to patients with more persistent AF or
higher disease-dependent stroke risk. In these patients
AHA/ACC guidelines continue to provide a reasonable
basis for guiding ongoing antithrombotic therapy after
ablative intervention (15).
Antiarrhythmic drug failure. Patients treated with antiar-
hythmic drugs had high early AF recurrence rates, which is
ot surprising given the frequency of baseline AF. Aggres-
ive follow-up monitoring may have detected more recur-
ences than seen in other trials. Furthermore, almost all
f these patients were treated with alternative antiar-
hythmic drug therapy during a comparable blanking
eriod, and 89% of drug-treated patients completed the
lanking period without crossing over. This allows a
easonable comparison of antiarrhythmic drug and cryo-
blation effectiveness based on equivalent blanking peri-
ds, unlike other past trials using different ablation and
rug treatment arm blanking periods (7).
afety outcomes of cryoballoon and drug therapy for
F. The prespecified safety endpoints in STOP AF, de-
ned as low rates of cryoablation procedure events and
ajor AF events, were both met. The presentation of all
dverse events in Table 2 occurring over a total of 12
onths follow-up provides a more comprehensive assess-
ent of the safety profile of this therapy than previouslyvailable. When viewed within this context, the event ratesn this trial are as low as seen in recently reported AF
blation studies (7,10–14).
ulmonary vein stenosis. Although other studies of
ryoballoon catheter ablation have suggested little to no PV
tenosis risk (9), this study demonstrates the possibility of
his adverse event, as does an additional case of
ryoablation-related PV stenosis reported by others (21).
he use of PV cross-sectional area in the primary analysis is
sensitive measure, which overstates the degree of clinically
elevant PV stenosis. Other clinical reports (2) have defined
V stenosis as a 70% to 75% reduction in vein diameter,
ather than the cross-sectional area used in this trial. The
ccurrence of stenosis appears related to ablation within the
ein, or due to repeated interventions at that site.
trial-esophageal fistula. Atrial-esophageal fistula forma-
ion was not seen in any patient in this study, possibly
eflecting differences in the histopathology of cryothermy
ith infrastructural sparing, compared with that seen with
F energy (22–23). Esophageal ulcers with cryoablation
nergy delivery have been reported (22, 24), which resolved
pontaneously or with protein pump inhibitor therapy, and
ecently a case of atrial/esophageal fistula was reported after
ulmonary vein cryoablation using a 23-mm balloon (25).
here does not appear to be a relationship between ulcer
ormation and a true atrial-esophageal fistula.
eurological events. Stroke may occur after cryoballoon
blation as evidenced by the single procedure-related stroke
n a patient crossing over from drug to ablative therapy. The
ther 4 neurological events occurred between 1 and 8
onths following cryoablation, suggesting a closer relation-
hip with the natural history of AF and anticoagulant
herapy than the ablation procedure itself, although the
HADS2 scores in these patients were 1.
Phrenic nerve injury. Phrenic nerve injury has been pre-
viously described in association with cryoballoon ablation
(19,20). This has been observed in 11.2% of original and
cross-over ablation procedures in this study but was largely
reversible (19). Similar transient phrenic nerve injury rates
from 8% to 11% have been reported in other early European
studies (13,19,26). Because the protocol mandated
follow-up inspiratory and expiratory chest radiographs in all
patients, detection of phrenic nerve injury was maximized in
this study. The mechanism of the occurrence of phrenic
nerve injury is probably related to positioning the balloon
further into the RS or RI PVs, as the phrenic nerve may run
behind the right atrium. Undersizing of the balloon to a
23-mm versus a 28-mm balloon, relative to the size of the
vein could contribute to this complication (14,19), as could
PV distortion with balloon inflation (27). It remains unclear
whether phrenic nerve pacing would be effective in prevent-
ing this complication (19,27–29), although early detection
with phrenic nerve pacing may be expected to accelerate
recovery of the nerve, if injured.
Other cardiac and vascular events. Other anticipated
adverse events as shown in Table 2 were similar to those
expected with other catheter-based ablative interventions
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tion was very uncommon in these patients, suggesting less
pericardial injury with cryoablation. The mechanism of
postprocedure cough is unclear but suggests airway irritation
that is reversible over time. Whether other mediators are
involved is unclear. It is impossible to know whether this is
related to cryothermy itself, although direct cryo bronchial
injury has been observed on bronchoscopy in a single patient
undergoing AF ablation (33).
Study limitations. Although this is the largest randomized
evaluation of cryoballoon ablation reported to date, there are
several important limitations to be considered. First, the
trial is limited by the frequency and timing of crossovers
from drug treatment to cryoablation. While this does not
negate the effectiveness of cryoablation, it renders it more
difficult to directly compare ablation and drug therapy
beyond the median 186 days to cross-over. Nevertheless, the
number of drugs previously failed and the median doses
taken were equivalent in both groups. All other demograph-
ics were also similar, suggesting the appropriateness of a
comparison of these patients. The limited choice of antiar-
rhythmic drugs may also have contributed to the high AF
recurrence rate observed in the drug-treated patients, al-
though agents used were similar to those in other recent
clinical trials. The use of dofetilide, dronedarone, or amio-
darone, not permitted by the FDA in this study, might have
increased the success rate of drug therapy.
Conclusions
The STOP AF trial demonstrates that cryoballoon ablation
is effective in preventing recurrent, symptomatic, paroxys-
mal AF in patients who are resistant to at least one
antiarrhythmic drug. PV isolation can be achieved in most
patients using the cryoballoon alone. Nevertheless, like
other treatment modalities, complications affecting PVs and
the phrenic nerve are possible.
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